Database of CDX Models - Creative Biolabs

To facilitate preclinical in vivo PD/PK and toxicological studies as well as in vivo efficacy evaluation of potential cancer immunotherapies, Creative Biolabs has established over 200 validated and well-characterized CDX models as well as luciferase-labeled CDX models for your choice. Our broad range of cell lines ensure a large variety of research options for your candidates.

Solid Tumor CDX Models

Type	Tumor Cell Line
Adrenal	H295R
■ Brain Cancer	LN-229, SF-295, SK-N-AS, U87 MG, U251
■ Breast Cancer	2LMP, 4T1, Bcap-37, BT20, BT474, DU4475, EMT6, HCC-70, HCC-1806, HCC-1954, JIMT-1, KPL-4, MCF-7, MCF-7-luc, MDA-MB-157, MDA-MB-231, MDA-MB-231-luc, MDA-MB-453, MDA-MB-468, MDA-N, Mx-1, SKBr-3, SUM159, T47D, ZR-75-1, ZR-75-30
■ Bladder Cancer	BFTC905, HT-1197, HT-1376, J82, RT4, SCaBER, SW780, 5637, T24, UM-UC3
■ Bone Cancer	U-2 OS
■ Cervical Carcinoma	AN3 CA, ECC-1, HEC-1-A, ME-180, MFE-280, Hela, Hela-luc, KB-3-1
■ Colorectal Cancer	CL-34, Colon137, COLO 201, COLO 205, COLO 320 DM, CT-26, CW-2, DLD-1, HCT-15, HCT-8, HT-29, HT-29-luc, HCT 116, HCT116 P53 K0(-/-), KM12, LoVo, LS-174T, LS-180, LS411N, LS1034, NCI-H716, RKO, SW48, SW403, SW480, SW620, SW837, WiDr
■ Endometrium Cancer	HEC-1B
■ Epidermoid Carcinoma	A-431
■ Gallbladder Carcinoma	Mz-ChA-1, Mz-ChA-2, Wittier
■ Gastric Carcinoma	AGS, AGS-luc, BGC-823, HGC-27, Hs746T, MGC-803, MKN-1, MKN-28, MKN-45, MKN-45-luc, NCI-N87, NUGC-4, NUGC-4-luc, SCH, SGC-7901, SNU-5, SNU-16, SNU-16-luc, Hs 746T
■ Glioma	LN-229, U-87 MG, U-87 MG-luc, U-373, U-343
■ Head and neck Cancer	CRL-1624, FaDu, KB
■ Liver Cancer	Bel-7402, HCCLM3, HCCLM3-luc, Hep3B2.1-7, Hep3B, Hep3B-luc, HepG 2, HepG 2-luc, HuH-7, PLC/PRF/5, SNU-398, QGY-7703, SK-HEP-1, SMMC-7721
■ Lung Cancer	95-D, A-427, A549, A549-luc, Calu-1, Calu-3, Calu-6, COR-L23, DMS114, H23, H69, H82, H211, H510, H526, H1299, H1975, H226, H292, H2171, H358, H441, H460, H520, H522, H647, H727, H810, H1581, H1650, H1792, H1993, H2009, H2030, H2228, H358, HCC-15, HCC-44, HCC-827, KLN205, LL/2, LLC1, MSTO-211H, NCl-H69, NCl-H146, NCl-H209, NCI-H226, NCI-H446, NCI-H460, NCI-H466, NCI-H520, NCI-H522, NCI-H526, NCl-H720, NCl-H1155, NCI-H1688, NCl-H1770, NCI-H1781, NCI-H1975, NCI-H1963, NCI-H1975-luc, NCl-H2106, NCI-H2122, NCI-H2126, NCI-H2228, PC-10, QG-56, SHP-77, SK-MES-1, SW1573
■ Melanoma	A2058, A375, A375-luc, B16, C32, CHL-1, COLO 800, HMCB, IGR-1, IGR-37, M-13, MDA-MB-435s, MeWo, SK-MEL-5, SK-MEL-30, UACC-62, WM98-1
■ Mesothelioma	MSTO-211H
■ Nasopharyngeal Carcinoma	S18, S26
■ Neuroblastoma	IMR5-75, Kelly, SK-N-MC, SK-N-SH, SKNAS
■ Ovarian Cancer	A2780, A2780l-luc, ES-2, HOC-22, HO-8910PM, PA-1, IGR0V1, OV-90, OVCAR-3, OVCAR-5, OVCAR-8/ADR, SK-OV-3, TOV-21G
■ Pancreatic Cancer	AsPC-1, BxPc-3, BxPc-3-luc, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF II, Hup-T3, KP4, MIA, MIA-luc, MiaPaCa-2, PaCa-2, PaCa-2-luc, PANC-1, Patu-8902, PSN-1
■ Prostate Cancer	22Rv.1, CL-1, DU 145, LNCaP clone FGC, PC3, PC-3M-luc, VCaP
■ Renal Carcinoma	A498, ACHN, Caki-1, Caki-2, 786-O, 786-O-luc, G-401, G-402, OS-RC-2, RENCA
■ Rhabdomyosarcoma	A-673
■ Sarcoma	HT-1080, MG-63, RD-ES, SJSA-1, S-180
■ Skin Cancer	Clone M3
■ Thyroid Cancer	8505C, FTC-238, K1
■ Uterine	ECC-1, HEC-1-A, HEC-1-B, MFE-280
■ Vulva Cancer	A-431

Hematological Malignancies CDX Models

Type	Tumor Cell Line
■ Acute Lymphoblastic Leukemia	KARPAS-299, MOLM-13, MOLT-4, NALM-6, Jurkat, E6-1, CCRF-CEM
■ Acute Monocytic Leukemia	U937, THP-1, MV4-11, MV4-11-luc
■ Acute Myeloid Leukemia	EOL-1, HL-60, KG-1, MV4-11
■ Acute Myeloblastic Leukemia	Kasumi-1, Kasumi-3(CD33+)
■ Acute Promyelocytic Leukemia	HL-60
■ Chronic Myeloid Leukemia	K-562, K-562-luc
■ Eosinophilic Leukemia	EOL-1
■ Erythro Leukemia	TF-1
■ Histiocytic Lymphoma	U-937
■ Megakaryoblastic Leukemia	SET-2
■ Multiple Myeloma	H929, KMS-11, KMS-26, KMS-12-BM, OPM-2, RPMI 8226, SK-MM-2, 8226-luc, ARH-77, ML-2
■ Non-Hodgkin Lymphoma	DoHH-2, Daudi, Farage, Granta 519, JEKO-1, KARPAS-299, Namalwa, Raji, Raji-luc, Ramos, REC-1, RL, SU-DHL-1, SU-DHL-4, WSU-DLCL2
■ Lymphoma (B-cell)	Mino, Namalwa

With experienced scientists and substantial breadth of services, Creative Biolabs can assist in selecting the most appropriate CDX model to fit your candidates and cancer type. Customized CDX models are also available upon request. Please contact us for detailed information, and we are looking forward to working with you.